The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1523
Obalon Balloon System - Another Gastric Balloon for Weight Loss
The full article is available to subscribers Subscriber Login   

The FDA has approved the Obalon Balloon System (Obalon), a swallowable intragastric gas-filled balloon device, to facilitate weight loss in adults with a body mass index (BMI) of 30-40 kg/m2 who have not been able to lose weight through diet and exercise. Two other gastric balloon devices, ReShape and Orbera, were approved earlier.1

WEIGHT LOSS PROCEDURES — Surgical treatment of obesity is generally limited to patients with a BMI ≥40 kg/m2, or a BMI ≥35 kg/m2 with an obesity-related comorbidity such as diabetes, hypertension, or hypercholesterolemia. Procedures that cause malabsorption (Roux-en-Y gastric bypass and bilio-pancreatic diversion) lead to greater weight loss, but also have more adverse effects than purely restrictive procedures such as adjustable gastric banding or sleeve gastrectomy. ... more       Show References Hide References

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Immediate Online access to current issue and archives from 1988 to the present
  • Mobile access to our mobile site and free apps for iOS, Android and Kindle
  • FREE online per issue CME/CE
Free trial offer
3 Free Issues of The Medical Letter on Drugs and Therapeutics mailed to your home or office PLUS online access.
Try a Free Trial Subscription
Purchase this article:
Title: Obalon Balloon System - Another Gastric Balloon for Weight Loss
Article code: 1523d
 Electronic, downloadable article - $25